List of Vaccines Companies in New York - 24

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients’ needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients' needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

CastleVax uses Newcastle Disease Virus (NDV) as a platform for rapidly developing safe and highly immunogenic viral vectors for use as vaccines, that are easy to deliver and store, and can be administered via injection or intranasally.

At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of human-centric healthcare, by transforming research, and advancing health together. Uniquely, we combine the experience of specialty laboratories with the global reach of a central lab. We have a worldwide network of 1000 labs, hold data from over 85 million patients across five continents, and have the ability to sequence 1000-plus whole human genomes per week. This unparalleled approach to patient data gives you the opportunity to have one partner for all your test services, with consistent access and support across all clinical trial phases.

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Creative Biostructure is specialized in providing cost-effective contract services to both academia and biotech/pharmaceutical industries in the field of structural biology and membrane protein technologies. We have developed all-in-one, gene-to-structure pipelines for the structure determination of macromolecules of your interest. With a team of experienced professionals, Creative Biostructure is able to solve the structure of many challenging proteins including GPCRs, ion channels, transporters, enzymes and viral targets. We also provide a comprehensive list of products and other related services to facilitate your research in structural biology. Creative Biostructure has also built up a unique and comprehensive Membrane Protein Screening Platform. Aiming at elucidating the fundamentals of membrane protein systems, we provide gene-to-structure services on the purification, crystallization, structure determination and analysis of various membrane proteins. With our state-of-the-art platforms, we are offering our customers access to the latest tools, techniques and expertise for their structural biology projects with competitive pricing and short turnaround time. Our staff will be very glad to discuss the details of your project and develop experimental strategies tailored to your requirements.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.

Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.

Virology research products

Spindle Biotech Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) is commercializing a proprietary RNA polymerase for large-scale mRNA vaccine production. Recent advances in mRNA technology have shown the growing importance of synthetic RNA in biological systems due to its desirable transient property. Typical mRNA vaccine companies spend up to 60% of their cost of goods on raw materials such as enzymes and DNA templates. Spindle's platform provides a unique solution in producing high-quality RNA on-demand and in high yield, significantly reducing the cost of goods for mRNA production.

LineaRx, an Applied DNA Sciences, Inc. company (NASDAQ: APDN) delivers enzymatically-produced LinearDNA™ as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (“PCRâ€?) based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

Oravax Medical is developing an oral COVID-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.